| Publication type: | Article in scientific journal |
| Type of review: | Peer review (publication) |
| Title: | Re: "A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder" by Strawn et al. : concerning harm-benefit ratio in a recent trial about Escitalopram for generalized anxiety disorder |
| Authors: | Plöderl, Martin Horowitz, Mark A. Hengartner, Michael P. |
| et. al: | No |
| DOI: | 10.1089/cap.2023.0029 |
| Published in: | Journal of Child and Adolescent Psychopharmacology |
| Volume(Issue): | 33 |
| Issue: | 7 |
| Page(s): | 295 |
| Pages to: | 296 |
| Issue Date: | Sep-2023 |
| Publisher / Ed. Institution: | Mary Ann Liebert |
| ISSN: | 1044-5463 1557-8992 |
| Language: | English |
| Subjects: | Adolescent; Child; Human; Escitalopram; Anxiety disorder |
| Subject (DDC): | 615: Pharmacology and therapeutics 616.8: Neurology, diseases of nervous system |
| URI: | https://digitalcollection.zhaw.ch/handle/11475/28790 |
| Fulltext version: | Published version |
| License (according to publishing contract): | Licence according to publishing contract |
| Departement: | Applied Psychology |
| Organisational Unit: | Psychological Institute (PI) |
| Appears in collections: | Publikationen Angewandte Psychologie |
Files in This Item:
There are no files associated with this item.
Show full item record
Plöderl, M., Horowitz, M. A., & Hengartner, M. P. (2023). Re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder” by Strawn et al. : concerning harm-benefit ratio in a recent trial about Escitalopram for generalized anxiety disorder. Journal of Child and Adolescent Psychopharmacology, 33(7), 295–296. https://doi.org/10.1089/cap.2023.0029
Plöderl, M., Horowitz, M.A. and Hengartner, M.P. (2023) ‘Re: ‘A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder’ by Strawn et al. : concerning harm-benefit ratio in a recent trial about Escitalopram for generalized anxiety disorder’, Journal of Child and Adolescent Psychopharmacology, 33(7), pp. 295–296. Available at: https://doi.org/10.1089/cap.2023.0029.
M. Plöderl, M. A. Horowitz, and M. P. Hengartner, “Re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder” by Strawn et al. : concerning harm-benefit ratio in a recent trial about Escitalopram for generalized anxiety disorder,” Journal of Child and Adolescent Psychopharmacology, vol. 33, no. 7, pp. 295–296, Sep. 2023, doi: 10.1089/cap.2023.0029.
PLÖDERL, Martin, Mark A. HOROWITZ und Michael P. HENGARTNER, 2023. Re: „A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder“ by Strawn et al. : concerning harm-benefit ratio in a recent trial about Escitalopram for generalized anxiety disorder. Journal of Child and Adolescent Psychopharmacology. September 2023. Bd. 33, Nr. 7, S. 295–296. DOI 10.1089/cap.2023.0029
Plöderl, Martin, Mark A. Horowitz, and Michael P. Hengartner. 2023. “Re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder” by Strawn et Al. : Concerning Harm-Benefit Ratio in a Recent Trial About Escitalopram for Generalized Anxiety Disorder.” Journal of Child and Adolescent Psychopharmacology 33 (7): 295–96. https://doi.org/10.1089/cap.2023.0029.
Plöderl, Martin, et al. “Re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder” by Strawn et Al. : Concerning Harm-Benefit Ratio in a Recent Trial About Escitalopram for Generalized Anxiety Disorder.” Journal of Child and Adolescent Psychopharmacology, vol. 33, no. 7, Sept. 2023, pp. 295–96, https://doi.org/10.1089/cap.2023.0029.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.